Angiodroid

Angiodroid is an Italian medical technology company founded in 2013, dedicated to developing innovative medical devices for angiographic procedures. Its flagship product, Angiodroid The CO2 Injector, is the first patented, CE-marked automatic injection system designed for CO2 angiography, providing a safer alternative to traditional iodinated contrast agents, particularly for patients at risk of kidney injury. The company integrates various departments, including research and development, sales, marketing, and clinical support, to efficiently manage projects and enhance customer satisfaction. Angiodroid specializes in vascular surgery, interventional radiology, interventional cardiology, and interventional angiology. It offers services such as clinical support during procedures, technical maintenance, and collaboration on clinical studies. In 2023, Angiodroid transitioned to a joint stock company, reflecting its growth and ambition to expand internationally. The company aims to make its CO2 injector available in hospitals worldwide, focusing on improving patient safety and clinical outcomes.

• Employees 44
• Founded 2013
• Annual Revenue $7500000
• Total Funding $9005830